Eris Lifesciences
- Market cap
- ₹ 15,246 Cr.
- P/E
- 21.8x
- P/B
- 3.98x
- 52-week range
- 1,069 – 1,740
- ROE
- 19%
- ROCE
- 14%
- Dividend yield
- 0.6%
- Debt / equity
- 0.6
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Eris Lifesciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)21.8 against a typical 34.3: cheaper than most peers (1st = cheapest).72nd of 220
- Sales growth+12.9% against a typical +15.6% from a year earlier.108th of 197
- Profit growth+14.4% against a typical +18.9% from a year earlier.92nd of 160
- Share price, 3 months−17.7% against a typical −0.5%.172nd of 200
- Size₹ 15,246.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).31st of 199
Latest announcements
Exchange filings and their impact on the company.
- Strong 12-13% sales growth and operating cash flow offset by one-off charge and margin dip, with tax benefit lifting profit.
Eris Lifesciences reported Q2 FY27 consolidated revenue of Rs 892.37 crore, up 12.6% from last year, and net profit of Rs 187.14 crore, up 39%. Profit included a Rs 35.9 crore exceptional write-down for an at-risk product settlement, offset by a tax credit after NCLT approval of the amalgamation of Aprica and Oaknet domestic business into Eris Therapeutics. Strong sales growth and Rs 637 crore half-year operating cash flow support earnings, though operating margin slipped to 26.8% from 28% last year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA | Stable | 8 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 May 2026 | Reaffirmed | IND AA | — | India Ratings | ₹ 2,448 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 26 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 29 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 20 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 24 Nov 2025 | Fund Raising | To consider issuance of equity shares of the Company by way of a preferential issue |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating Profit | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% |
| Other Income | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | −17 | 2 | 2 |
| Interest | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 3% | 12% | −4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | −75% | 20% |
| Net Profit | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS in Rs | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 18%
- 5 Years
- 21%
- 3 Years
- 23%
- TTM
- 10%
- 10 Years
- 17%
- 5 Years
- 12%
- 3 Years
- 19%
- TTM
- 69%
- 10 Years
- —
- 5 Years
- 13%
- 3 Years
- 17%
- TTM
- —
- 10 Years
- 21%
- 5 Years
- 18%
- 3 Years
- 16%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Eris Lifesciences | ₹ 1,174.00 | ₹ 15,246 Cr. | 21.8x | 4x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Amit Indubhushan Bakshi
- Executive Chairman of the Board, Managing Director
- Sachin Shah
- Chief Financial Officer
- Krishnakumar Vaidyanathan
- Chief Operating Officer, Executive Director
- Milind Talegaonkar
- Compliance Officer, Company Secretary
- Inderjeet Singh Negi
- Executive Director
- Kaushal Kamleshkumar Shah
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.